Suvorexant for Treatment of AUD and PTSD

PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)Insomnia
Interventions
DRUG

Suvorexant

Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.

OTHER

Placebo

Film coated tablet to match the active drug.

Trial Locations (2)

77054

RECRUITING

The University of Texas Health Science Center - Houston, Houston

90095

RECRUITING

University of California - Los Angeles, Los Angeles

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

The University of Texas Health Science Center, Houston

OTHER

lead

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

OTHER

NCT06679062 - Suvorexant for Treatment of AUD and PTSD | Biotech Hunter | Biotech Hunter